NEW YORK, Sept. 13, 2017
/PRNewswire/ -- The global cell-based assays market is expected to
reach USD 19.92 billion by 2022, at a
CAGR of 8.4% from 2017 to 2022. The major factors driving this
market are the growing funding and investments in R&D, the
increasing prevalence of chronic disorders, rising drug discovery
activity, and the advantages of cell-based assays over alternative
technologies.On the other hand, the growth of this market is
hindered to some extent due to the high cost of instruments and
stringent regulatory policies
Read the full report: https://www.reportlinker.com/p05099513
Consumables to register the highest CAGR during the forecast
period
The cell-based assays market is classified on the basis of products
into consumables, instruments, services and software. The
consumables segment is further segmented into reagents, assay kits,
microplates, cell lines, probes & labels and other
consumables.The consumables segment is expected to grow at the
highest rate during the forecast period. This is attributed to the
effective and innovative products developed and launched by various
players in the market. Such products are encouraging acceptance
from consumers.
Pharmaceutical and biotechnology companies to dominate the
cell-based assays market during the forecast period
The cell-based assays market is segmented by end users into
pharmaceutical and biotechnology companies, academic and government
institutions, contract research organizations, and other end users
such as hospitals, clinical laboratories, and environmental
monitoring laboratories. In 2017, pharmaceutical and biotechnology
companies segment is expected to command the largest share and is
also estimated to grow at the fastest rate as compared to the other
segments. This positive growth can be attributed to the increasing
adoption of cell-based assays for drug discovery by these end
users, particularly in developed countries across North America and Europe.
APAC is estimated to be the fastest growing regional segment in
the global cell-based assays market during the forecast
period
Geographically, the cell-based assays market is dominated by
North America, followed by
Europe. The Asia-Pacific region is estimated to grow at
the fastest rate which can be attributed to the increased
investments in the healthcare sector, rising expenditure on
healthcare along with increased coverage of health insurance, and a
rise in disposable incomes especially in countries like
China, Japan, and India.
The primary interviews conducted for this report can be
categorized as follows:
• By Company Type - Tier 1 â€" 25 %, Tier 2 â€" 35% and Tier 3
â€" 40%
• By Designation â€" C level â€" 35%, Director level â€" 25%,
Others â€" 40%
• By Region â€" North America -
43%, Europe â€" 19%, APAC â€" 29%,
RoW â€" 9%
The key players in the market are Merck KGaA (Germany), Becton, Dickinson and Company
(U.S.), PerkinElmer Inc. (U.S.), Promega Corporation (U.S.),
Danaher Corporation (U.S.), GE Healthcare (U.K), Thermo Fisher
Scientific Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.),
BioTek Instruments, Inc. (U.S.), Lonza Group (U.S.), ProQinase GmbH
(Germany), Charles River
Laboratories, Inc (U.S.), Cisbio Bioassays (France), Miltenyi Biotec (Germany), Cell Biolabs, Inc. (U.S.), DiscoverX
Corporation (U.S.), Marin Biologic Laboratories (U.S.), Biospherix,
Ltd (U.S.), Essen BioScience Inc. (U.S.), Life Technologies
Corporation (U.S.), BioAgilytix Labs. (U.S.), Enzo Life Sciences,
Inc. (Switzerland), Aurelia
Bioscience Ltd. (U.K. ), Selexis SA (U.S.), and QGel SA
(Switzerland).
Research Coverage:
The report analyses the cell-based assays market by products,
applications, end users, and regions. Apart from a comprehensive
geographic & product analysis and market sizing, the report
also provides the competitive landscape that covers the growth
strategies adopted by industry players over the last three years.
In addition, the company profiles comprise of product portfolios,
developments, and strategies adopted by key players to maintain and
increase their shares in the market. The market research data,
current market size, and forecast of the future trends in the
market will help established players as well as new entrants make
necessary decisions regarding product offerings, geographic focus,
change in strategic approach, and levels of output to remain
successful in the cell-based assays market.
Key benefits of buying the Report:
This report will enable both established firms as well as new
entrants/smaller firms to gauge the pulse of the market, which in
turn will help these firms garner greater market shares. Firms
purchasing the report can use any one or a combination of the
below-mentioned strategies to strengthen their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product
portfolios of the top players in the cell-based assays market
• Product Development/Innovation: Detailed insights on the
upcoming technologies, R&D activities, and product launches in
the cell-based assays market
• Competitive Assessment: In-depth assessment of the market
strategies, geographic and business segments, and product
portfolios of the leading players in the cell-based assays
market
• Market Development: Comprehensive information about emerging
markets. This report analyzes the market for various cell-based
assays across geographies
• Market Diversification: Exhaustive information about new
products, untapped geographies, recent developments, and
investments in the cell-based assays market
Read the full report: https://www.reportlinker.com/p05099513
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original
content:http://www.prnewswire.com/news-releases/cell-based-assays-market-by-product-application-end-user-global-forecast-to-2022-300519064.html
SOURCE Reportlinker